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Abstract: Endothelial cells (ECs) maintain vascular integrity and mediate vascular repair and angiogenesis, by which 
new blood vessels are formed from pre-existing blood vessels. Hyperglycemia has been shown to increase EC an-
giogenic potential. However, few studies have investigated effects of fatty acids (FAs) on EC angiogenesis. Cluster of 
differentiation 36 (CD36) is a FA transporter expressed by ECs, but its role in EC proliferation, migration, and angio-
genesis is unknown. We sought to determine if circulating FAs regulate angiogenic function in a CD36-dependent 
manner. CD36-dependent effects of FAs on EC proliferation and migration of mouse heart ECs (MHECs) and lung 
ECs (MLECs) were studied. We used both silencing RNA and antisense oligonucleotides to reduce CD36 expression. 
Oleic acid (OA) did not affect EC proliferation, but significantly increased migration of ECs in wound healing ex-
periments. CD36 knockdown prevented OA-induced increases in wound healing potential. In EC transwell migration 
experiments, OA increased recruitment and migration of ECs, an effect abolished by CD36 knockdown. Phospho-
AMP-activated protein kinase (AMPK) increased in MHECs exposed to OA in a CD36-dependent manner. To test 
whether in vivo CD36 affects angiogenesis, we studied 21-day recovery in post-hindlimb ischemia. EC-specific CD36 
knockout mice had reduced blood flow recovery as assessed by laser Doppler imaging. EC content in post-ischemic 
muscle, assessed from CD31 expression, increased in ischemic muscle of control mice. However, mice with EC-
specific CD36 deletion lacked the increase in CD31 and matrix metalloprotease 9 expression observed in controls. 
EC expression of CD36 and its function in FA uptake modulate angiogenic function and response to ischemia, likely 
due to reduced activation of the AMPK pathway. 
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Introduction
Endothelial cells (ECs) line vessel walls, main-
tain vascular integrity, and form a permeability 
barrier that allows selective molecule trans-
port. ECs also regulate vascular tone and 
release factors that mediate blood clotting, 
thrombolysis, and cell infiltration through the 
endothelium [1]. ECs promote vascular repair 
and angiogenesis. Unlike vasculogenesis, 
which occurs at the developmental stages, 
angiogenesis allows new vessels to form by 
sprouting from pre-existing vessels, promoting 
blood supply to expanding tissues [2]. Under 
pathological ischemic injury, angiogenesis is 
required for injury repair. Vascular endothelial 
growth factors (VEGFs) regulate angiogenesis 
[3] by controlling proliferation and migration of 
ECs and production of matrix metalloproteas- 
es (MMPs) [4]. MMPs drive matrix degradation 
required for EC invasion and vessel sprouting. 
VEGFα and its receptor VEGFR2 are stimulators 
of angiogenesis, whereas VEGFβ and its re- 
ceptor VEGFR1 are negative regulators that 
limit angiogenic effects of VEGFα/VEGFR2 [5, 
6]. MMP9 and MMP2 are regulated by a family 
of tissue inhibitors of MMPs (TIMPs) [7, 8], 
composed of TIMP1-TIMP4 [9, 10]. TIMP1 and 
TIMP3 regulate MMP9, whereas TIMP2-TIMP4 
regulate MMP2 [11].
Hyperglycemic effects on EC function have 
been widely studied [12, 13], showing increas- 
ed EC angiogenesis, particularly in pathological 
disorders such as diabetic retinopathy [14, 15]. 
However, few studies have investigated the 
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effects of lipid metabolism on angiogenesis. 
Cluster of differentiation 36 (CD36) is a multi-
ligand receptor that functions as a fatty acid 
(FA) transporter [16, 17] and influences cyto-
kine release and signaling [18, 19], calcium 
flux, insulin signaling [20, 21], and platelet 
function [22, 23]. The role of CD36 as a FA 
transporter was identified in adipocytes (na- 
med fatty acid translocase, FAT) [24-26]. 
However, CD36 is also expressed in ECs, mo- 
nocytes, macrophages, platelets, epithelial 
cells, cardiomyocytes, and skeletal muscle 
[19]. CD36 expression is regulated by lipid- 
activated peroxisome proliferator-activated 
receptors (PPARs), particularly PPARγ [27]. 
Increased FA uptake results in binding of the- 
se molecules to PPARs at the surface of the 
nucleus. In turn, PPARs translocate and dimer-
ize with the nuclear receptor RXR resulting in 
the modulation of CD36 gene transcription 
[27]. Cellular CD36 is localized in specializ- 
ed cholesterol-rich membrane microdomains. 
Phosphatidylcholine and phosphatidylserine 
on lipoproteins and apoptotic cells are also 
ligands for CD36. Moreover, the Src family of 
non-receptor tyrosine kinases interacts with 
CD36 to alter several downstream processes 
[28]. 
CD36 is more abundant in microvascular than 
macrovascular ECs [29], but how CD36 levels 
impact the functions of the two cell types 
remains unknown. A substantial number of 
studies have investigated the role of CD36 in 
microvascular ECs based on its function as a 
thrombospondin-1 (TSP-1) receptor, showing 
that CD36 is anti-angiogenic [30]. Inhibition 
of CD36 in microvascular ECs prevents the for-
mation of a SHP-1/VEGFR2 complex, thereby 
blocking EC migration and tube formation. 
SHP-1 mediates an anti-angiogenic pathway 
that is induced by the interaction of CD36 
with TSP-1, which blocks VEGFR2 signaling. 
However, there is a lack of knowledge on the 
role of CD36 in FA metabolism in vascular ECs. 
We tested whether CD36 interactions with 
long-chain FAs (LCFAs) affect microvascular 
and macrovascular EC functions by studying 
the role of CD36 in vascular repair in peri- 
pheral vascular disease. Using cultured ECs 
and mice with EC-specific CD36 deletion, we 
show that CD36 affects EC-mediated angio- 
genesis and that these actions are likely due to 
interactions with LCFAs rather than effects on 
cellular lipid oxidation. 
Materials and methods
Mouse heart and lung endothelial cell culture
Mouse heart ECs (MHECs, mVera-hrt-01) and 
mouse lung ECs (MLECs, mVera-lng-01) (An- 
giocrine Bioscience) were cultured in 12-well 
tissue culture plates (Sigma Aldrich) in com-
plete endothelial cell growth media containing 
10% FBS (Gibco). In functional assays, MHECs 
and MLECs were treated with bovine serum 
albumin (BSA) (Sigma Aldrich) (control), BSA-
bound oleic acid (OA, 300 µmol/L), BSA-bound 
linoleic acid (LA, 300 µmol/L), or BSA-bound 
palmitic acid (PA, 300 µmol/L, Agilent) for 16 
hours. In CD36 knockdown experiments, 
CD36 silencing RNA (siRNA) (50 nmol/L, 
Dharmacon) and CD36 antisense oligonucle-
otide (ASO) (50 nmol/L, Ionis Pharmaceuti- 
cals) were used with Lipofectamine RNAiMax 
(Invitrogen) transfection reagent.
mRNA expression by qRT-PCR
MHEC and MLEC mRNA expression was 
assessed by quantitative real-time PCR (qRT-
PCR) for mouse endothelial, angiogenic, and 
metabolic markers (Table S1). 
Proliferation assay
Proliferation of MHECs and MLECs treated 
with CD36 siRNA or CD36 ASO and OA was 
assessed by Ki67 mRNA expression using 
qRT-PCR and measured using a Fluorometric 
Proliferation Assay kit (BioVision). Relative fluo-
rescent units (RFUs) are directly proportional 
to the number of cells. The fluorometric assay 
used in this study is based on a nuclear dye 
which binds with high specificity to the nucleic 
acids in the cell and generates a green fluo- 
rescent signal which was detected using a 
fluorescence microplate reader (Ex/Em: 480/ 
538 nm). This assay provides sensitivity to 
detect a wide range of cell number, 25 to 
60,000 cells, which allows for more precise 
assessment of the effects on both cell survival 
and cell proliferation. 
Wound scratch assay
Migration potential of MHECs and MLECs was 
assessed using a wound healing assay sy- 
stem, as reported previously [31]. A scratch 
was manually made on seeded ECs using a 
100 μL pipet tip. Average wound scratch area 
was 20% of the surface of ECs seeded. After 
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16 hours of incubation in the presence of BSA, 
OA, LA, or PA, the wound area was imaged and 
measured. In a second set of experiments, 
MHECs and MLECs were treated with OA in 
the presence of CD36 siRNA or CD36 ASO in 
order to compare and confirm the effects of 
CD36 knockdown using two methods. For 
imaging, MHECs and MLECs were stained 
with Calcein-AM (Molecular Probes, 30 mins, 
37°C), and percentage wound closure was 
calculated between the 0 hour and 16 hour 
time point. Three replicates per condition were 
analyzed in every experiment and three field 
images were taken for each condition.
Transwell migration assay
MHEC and MLEC migration was evaluated by 
transwell migration assay. ECs transfected 
with CD36 siRNA or CD36 ASO were seeded 
in the top chamber of a 24-well plate insert, 
and migration towards OA (300 µmol/L) or 
control BSA was assessed after 16 hours. In a 
second set of experiments, ECs transfected 
with CD36 ASO were pre-treated with OA for 
16 hours prior to the transwell migration as- 
say and seeded on the top chamber in order 
to determine whether chronic presence of 
FAs affects EC angiogenic potential. Migration 
towards media containing 2% fetal bovine 
serum (FBS) (bottom chamber) was monitored. 
The inserts were stained with Calcein-AM dye 
(Molecular Probes 30 mins, 37°C), and data 
was collected using a fluorescence plate read-
er. RFUs were compared between the different 
conditions.
Matrigel tube formation assay 
MHECs and MLECs were incubated for 16 ho- 
urs in the presence of OA or control BSA, and 
tube formation was evaluated using a Matrigel 
matrix invasion assay. In a second set of ex- 
periments, ECs transfected with CD36 ASO 
were pre-treated with OA for 16 hours prior to 
tube formation assay in order to determine 
whether chronic presence of FAs affects EC 
angiogenic potential. Tubes were then stained 
with Calcein-AM dye, and the well-defined 
closed tube structures formed were counted to 
generate a ratio of fold change in number of 
tubes compared to control conditions (BSA). 
MMP release assay
Supernatants of MHECs and MLECs treated 
with BSA or OA for 16 hours were assessed 
in mouse MMP9 (MyBiosource) and MMP2 
(Abcam) ELISA colorimetric assays according to 
manufacturer’s instructions.
Western blot
MHECs and MLECs treated with BSA or OA 
with or without insulin for 16 hours were sub-
jected to SDS-PAGE protein analysis for phos-
pho-AMPK (AMP-activated protein kinase) α, 
AMPKα, and α-tubulin. 
Hindlimb ischemia mouse model
C57BL/6J control LoxP (EC-Cd36fl/fl named 
LoxP) and C57BL/6J Tie2 promoter-driven 
EC-specific CD36 knockout mice (EC-Cd36-/-) 
were used in hindlimb ischemia (HLI) studies 
performed by femoral artery ligation. All proto-
cols were approved by the New York Univer- 
sity Animal Research Committee (IACUC) and 
based on NIH guidelines. Animals were anes-
thetized using ketamine (100 mg/kg) and 
xylazine (10 mg/kg) by intraperitoneal injec- 
tion during the time of surgery and using 2% 
isoflurane inhalation at the time of Laser 
Doppler imaging. Buprenorphine (0.05 mg/ 
kg) was administered subcutaneously follow- 
ing the surgery every 12 hours for a total of 48 
hours (total of 4 doses) per animal. Vascular 
recovery was monitored over 7 and 21 days 
post-ischemia. Muscle tissues were collected 
for mRNA expression analysis and immuno- 
histological staining. At the end of the study, 
mice were euthanized by inhaled CO2 and cervi-
cal dislocation. 
Laser Doppler imaging
Blood flow imaging of EC-Cd36fl/fl and EC- 
Cd36-/- mice was performed at day 0 (immedi-
ately following ischemic injury), day 7, and day 
21 to assess collateral vessel formation and 
the restoration of flow in the hindlimb muscles. 
Protein expression by immunohistochemistry
Immunohistochemistry was performed on OCT 
embedded muscle tissues to assess CD36 
and CD31 protein expression at 21-day 
post-ischemia. 
Statistical analysis
All results are presented as the mean ± SEM of 
at least 3 independent experiments. Statisti- 
cal comparisons were performed using either 
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paired student’s t-test followed by a Mann-
Whitney post-test, one-way or two-way ANOVA 
as well as a Dunnett’s post-test for compari- 
son against the control group or the Bonferroni 
post-test for comparison between different 
groups. Statistical comparisons with P < 0.05 
and P < 0.01 were considered statistically sig- 
nificant. Comparisons between all treatment 
groups in gene expression analyses were used 
to show the effect of OA on EC gene expres- 
sion both with and without the effect of CD36 
inhibition. This approach allows for more spe-
cific measurement and deciphering of the 
effects of OA and CD36 inhibition separately. 
Moreover, we performed statistical analyses on 
the combination of CD36 inhibition and OA 
treatment. Statistical comparisons for each 
study have been specified in the Figure 
legends.
Results
CD36 knockdown does not affect cell survival 
and proliferation
ECs derived from different tissues show differ-
ent angiogenic potential and responses to 
VEGFs and inflammatory molecules, including 
interleukin-1β (IL-1β) [32]. We used MLECs 
and MHECs; the majority of MLECs are from 
capillaries, which are non-angiogenic vessels, 
while MHECs contain a mixture of ECs pre- 
dominantly derived from larger blood vessels 
[29]. In vivo differences in gene and protein 
expression of these ECs have been described, 
including endothelial markers VE-Cadherin, 
CD34, CD36, VEGFR2, and VCAM [29]. Micro- 
vascular ECs are organ specific and regulate 
metabolism. Microvascular ECs express higher 
levels of VCAM-1 than macrovascular heart 
ECs [29]. 
We first asked whether CD36 knockdown 
affects survival and proliferation of MHECs 
and MLECs. Microvascular MLECs had slightly 
higher CD36 mRNA expression compared to 
macrovascular MHECs, data not shown, as pre-
viously reported [29]. CD36 siRNA and ASO 
reduced CD36 expression by 80% in MHECs 
and 60% in MLECs compared to control ECs 
and non-targeting (NT) siRNA or NT ASO (Fi- 
gure 1A). It is important to note that EC trans-
fection utilizing siRNA does not achieve 100% 
knockdown of genes; 60-80% knockdown is 
widely reported in many studies for this cell 
type [33]. As assessed by measuring Ki67 
mRNA and a proliferation assay, CD36 knock-
down did not affect EC proliferation (Figure 
1B). We treated MHECs and MLECs with BSA-
bound OA and compared with BSA alone. No 
changes were noted in CD36-inhibited and 
OA-treated cells, suggesting that FAs do not 
induce cell death or increase EC proliferation 
(Figure 1B).
CD36 knockdown hinders EC migration during 
exposure to FAs
We then examined EC angiogenic functions by 
assessing wound healing potential of MHECs 
and MLECs transfected with CD36 siRNA, 
CD36 ASO, or control NT siRNA using a wound 
scratch assay. Wound closure in the presence 
of different BSA-bound FAs (OA, LA, or PA) was 
measured at 0 and 16 hours. Time-course 
experiments allowed us to determine that 16 
hours is the optimal migration time (data not 
shown). OA and LA stimulated both MHEC 
and MLEC migration with OA being more effi-
cient (Figure 2A). PA significantly reduced EC 
wound healing potential and was toxic, result-
ing in observable EC death. We elected to 
treat ECs with OA for the remaining experi- 
ments in this study. We tested whether CD36 
expression is required for improved migration 
with FAs. We found that CD36 knockdown 
impaired OA-mediated increases in wound 
healing potential in MHECs and MLECs (Figure 
2B, 2C). 
To assess EC migratory potential towards high 
FA environments, we performed a migration 
assay using transwell inserts where MHECs or 
MLECs, transfected with CD36 siRNA or ASO, 
were included in top chambers, while BSA-
bound OA or control BSA were added to bot- 
tom chambers. We did not utilize a migration-
inducing factor such as VEGF or serum as 
we did not want to drive MHEC migration by 
activating VEGFRs and consequently mask the 
potential impact of CD36 on EC migration. 
Control ECs, labelledNT siRNA- or ASO-treat- 
ed, significantly migrated towards OA whereas 
CD36-deficient ECs did not show increased 
migratory potential when stimulated with OA 
(Figure 3A, 3B). In parallel, we pretreated ASO-
transfected ECs with OA (16 hours), removed 
OA before the migration assay, and assessed 
EC migration towards media with 2% FBS. In 
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Figure 1. Effect of oleic acid on cell proliferation in CD36-defi-
cient MHECs and MLECs (A) siRNA- and ASO-mediated CD36 
knockdown in MHECs and MLECs. mRNA expression of CD36 
assessed by qRT-PCR. Histograms show fold change in CD36 
mRNA expression normalized to 18S mRNA expression of non-
targeting (NT) and CD36 siRNA or ASO-treated ECs compared 
to control (CTRL) ECs. Data represent mean ± SEM, n = 8, *P 
< 0.05, **P < 0.01 vs. CTRL. (B) Effect of oleic acid (OA, 300 
µmol/L) on siRNA-mediated CD36 knockdown on MHEC and 
MLEC proliferation assessed by Ki67 mRNA expression and 
fluorescence-based cell proliferation assay. Histograms show 
fold change in Ki67 mRNA expression normalized to 18S mRNA 
expression compared to ECs treated with non-targeting siRNA 
(NT siRNA). Data represent mean fold change ± SEM, n = 6; His-
tograms show fold change in RFU compared to NT siRNA ECs. 
Data represent ± SEM, n = 6. One-way ANOVA statistical tests 
were used to determine statistical significance.
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Figure 2. Effect of oleic acid on cell migration in CD36-deficient MHECs and MLECs. A. Effect of oleic acid (OA), lin-
oleic acid (LA), combination of OA+ LA or palmitic acid (PA) (300 µmol/L) on MHEC and MLEC migration compared to 
control (CTRL) ECs. Representative images of wound healing assays imaged at 0 h and 16 h. White lines were added 
to show the width of the wound. Histograms show percent wound closure over 16 hours. Data represent mean ± 
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these pretreatment studies, both ECs with 
CD36 knockdown and control ECs showed no 
differences in EC migration. These results 
confirm that OA-stimulated ECs lose their 
migratory potential in the absence of continu 
ed OA uptake (Figure 3C). We associated 
OA-induced migratory effect to CD36 expres-
sion rather than a proliferative effect as no 
changes in Ki67 expression and cell prolifera-
tion were measured (Figure 1B).
FAs and CD36 modulate EC tube formation 
To evaluate how CD36 influences MHEC and 
MLEC tube formation, ECs transfected with 
CD36 siRNA or ASO were plated on Matrigel 
matrix in the presence of BSA-bound OA or 
control BSA. OA promoted EC Matrigel inva- 
sion and tube formation, whereas CD36 
knockdown impaired tube formation (Figure 
3D). In ASO-transfected ECs pretreated with 
OA and then subjected to the tube formation 
assay, we noted loss of OA-induced closed-loop 
tubes (Figure 3E). These data together with 
those of transwell migration assays suggest 
that EC angiogenic potential is stimulated by 
chronic presence of high FA levels via CD36. 
CD36 knockdown downregulates FA-induced 
increases in EC angiogenic factors
The effects of CD36 knockdown on EC migra-
tion could be due to altered EC metabolism or 
activation of a signaling process consequent 
to CD36 ligation. To understand the mecha-
nism by which high FAs drive EC angiogenic 
function, we measured mRNA levels of CD36, 
CD31, and endothelial nitric oxide synthase 
(eNOS). As our goal is to investigate CD36 
functions in vascular repair in peripheral va- 
scular disease, we focused on MHEC gene 
expression because these macrovascular ECs 
function more similarly to the ECs found in 
large vessels of the peripheral muscle tissues 
in a hindlimb ischemia mouse model. It has 
been established that increased FAs can con-
tribute to atherosclerotic changes and result 
in macrovascular complications including in- 
sufficiency of blood flow to the extremities, 
which is a common manifestation of peri- 
pheral vascular disease [34]. MLEC gene 
expression data is included in the supplemen-
tary material (Supplementary Figures 1, 2). 
OA increased CD36 expression. CD36 knock-
down in MHECs reduced OA-mediated in- 
creases in CD31 expression (Figure 4A). OA 
upregulated expression of VEGFα, VEGFβ, and 
VEGFR1, while VEGFR2 trended higher (Figure 
4B). CD36 knockdown increased mRNA for 
VEGFα, VEGFR2, and VEGFR1 without affect- 
ing VEGFβ and reversed all regulatory effects 
of OA treatment, as outlined in statistical com-
parisons between OA-treated MHECs in which 
CD36 has been inhibited and MHECs which 
are CD36-deficient and were not treated with 
OA (Figure 4B). These comparisons provide rel-
evant insight as it provides a way to decipher 
the role of CD36 in FA metabolism in ECs 
and the associated effects on angiogenic func-
tion. Previous studies suggest VEGFβ regulat- 
es EC uptake of FAs by transcriptional regula-
tion of vascular FA transport proteins whereby 
VEGFβ-deficient mice display less lipid accu- 
mulation in heart and muscle [35]. We sug- 
gest that the inhibition of CD36 promotes an 
upregulation of VEGFα as a compensatory 
mechanism in order to maintain EC angio- 
genic function. Moreover, although CD31 is 
commonly used as an endothelial marker, it is 
specifically an adhesion molecule associated 
with platelet-endothelial adhesion. It may be 
used as a marker to detect both mature and 
immature/new ECs; thus, CD31 may be used 
as an adequate marker in in vivo studies. 
However, CD31 is also expressed in hemato- 
poietic cells [36]. We chose to investigate 
effects on VEGFα and VEGFR as they are 
angiogenic drivers that stimulate cell prolifera-
tion and impact downstream players such as 
MMPs in the process of angiogenesis whereas 
CD31 does not directly affect the angiogenic 
pathway. We have also previously shown that 
SEM, n = 6, *P < 0.05 vs. CTRL; B. Effect of oleic acid (OA, 300 µmol/L) on siRNA-mediated CD36 knockdown on 
MHEC and MLEC migration compared to NT siRNA ECs. Representative images of wound healing assays imaged at 
0 h and 16 h. White lines were added to show the width of the wound. Histograms show percent wound closure over 
16 hours. Data represent mean ± SEM, n = 6, *P < 0.05 vs. NT siRNA; C. Effect of oleic acid (OA, 300 µmol/L) on 
ASO-mediated CD36 knockdown on MHEC and MLEC migration compared to NT ASO ECs. Representative images of 
wound healing assays imaged at 0 h and 16 h. White lines were added to show the width of the wound. Scale bars 
represent 100 μm. Histograms show percent wound closure over 16 hours. Data represent mean ± SEM, n = 6, *P 
< 0.05 vs. NT ASO. Two-way ANOVA statistical tests were used to determine statistical significance.
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CD36 and CD31 co-localize in heart tissue 
capillaries [37]. Hence, in our in vivo studies we 
chose to assess CD31, VEGF and MMP expres-
sion in muscle tissues of a hindlimb ischemia 
mouse model. 
We measured gene expression levels of 
MMPs and their inhibitors, TIMPs. MMP9 ex- 
pression increased in MHECs treated with OA 
and CD36 siRNA compared to NT siRNA (Fi- 
gure 4C). OA, in combination with CD36 si- 
RNA, could not further increase MMP expres-
sion (Figure 4C). Although OA had no effect on 
MMP2 in MHECs, knockdown of CD36 in 
MHECs treated with OA significantly reduced 
MMP2 expression (Figure 4C). Hence, CD36 
inhibition increases MMP9 expression. In 
treatment with OA, CD36 knockdown reduced 
expression of MMP9 and MMP2. Moreover, 
OA-treated MHECs increased TIMP2 and TIM- 
P3 and reduced TIMP1 mRNA levels, whereas 
CD36 knockdown reduced TIMP1 and TIMP2. 
Although no differences were noted in MMP2 
gene expression, we show OA increased MMP2 
release by MHECs (Figure 4D). 
The data suggest that CD36 influences ex- 
pression of some VEGFs and MMPs in MHECs, 
which mediate EC migration and invasion po- 
tential and drive the ability to form new vas- 
culature. We examined whether these function-
al alterations are associated with metabolic 
changes in ECs by assessing metabolic gene 
expression in MHECs treated with OA and in 
CD36 knockdown. Metabolic genes carnitine 
palmitoyltransferase 1 (Cpt1) a, Cpt1b, glucose 
transporter 1 (GLUT1), and perilipin 2 (PLIN2) 
were upregulated in OA-treated MHECs. CD36 
knockdown reduced Cpt1a, but further in- 
creased Cpt1b, GLUT1, PLIN2, and AMPKα 
(Figure 5B). These genes were all further upreg-
ulated in the presence of OA, compared to 
MHECs treated with NT siRNA and OA alone 
(Figure 5). 
Alterations in metabolic gene expression in 
FA-treated MHECs suggest that CD36-de- 
pendent effects on EC angiogenic function 
correlate with changes in EC metabolism. 
Protein expression data showed phospho-
AMPK was significantly increased in macrovas-
cular MHECs exposed to high levels of OA, 
whereas total AMPK expression tended to 
decrease with CD36 knockdown in conditions 
with and without insulin. Upon interaction of 
FAs with the CD36 receptor, Fyn is released 
from the complex, allowing cytosolic liver kina- 
se B1 (LKB1) to activate AMPK [38]. Our data 
support these findings, as treating MHECs with 
OA caused increases in AMPK phosphorylation 
(Figure 5C).
We looked at the same endothelial angiogenic 
and metabolic factors in both our in vitro and 
in vivo systems. The mRNA expression data in 
our in vivo model provide evidence that in 
EC-Cd36-/- mice muscle tissues, there is upreg-
ulation of angiogenic factors by day 21 (not 
seen by day 7 - Supplementary Figure 4). CD36 
inhibition hinders the reparatory mechanism in 
muscle in vivo as it hinders similarly the migra-
tory function of MHECs in vitro.
Vascular recovery of EC-Cd36-/- mice under 
ischemic conditions 
We have recently shown that in heart tissues 
of EC-Cd36-/- mice, mRNA levels of PPARα are 
Figure 3. Effect of oleic acid on transwell migration and tube formation in CD36-deficient MHECs and MLECs. A. 
Effect of siRNA-mediated CD36 knockdown on MHEC and MLEC migration compared to NT siRNA ECs in transwell 
migration assays stimulated by oleic acid (OA, 300 µmol/L) or control BSA (bottom chamber). Histograms show fold 
change in RFUs of fluorescent-labelled EC migration. Data represent mean ± SEM, n = 6, *P < 0.05 vs. NT siRNA; 
B. Effect of ASO-mediated CD36 knockdown on MHEC and MLEC migration compared to NT ASO ECs in transwell 
migration assays stimulated by oleic acid (OA, 300 µmol/L) or control BSA (bottom chamber). Histograms show fold 
change in RFUs of fluorescent-labelled EC migration. Data represent mean ± SEM, n = 6, *P < 0.05 vs. NT ASO; 
C. Effect of ASO-mediated CD36 knockdown and pre-treatment with oleic (OA, 300 µmol/L) on MHEC and MLEC 
migration compared to NT ASO ECs in transwell migration assays stimulated by 2% fetal bovine serum (FBS) (bot-
tom chamber). Histograms show fold change in RFUs of fluorescent-labelled EC migration. Data represent mean ± 
SEM, n = 6. D. Effect of oleic acid (OA, 300 µmol/L) on ASO-mediated CD36 knockdown on MHEC and MLEC new 
vessel formation in Matrigel tube formation assays. Scale bars represent 100 μm. Histograms show fold change in 
a number of well-defined closed tube structures. Data represent mean ± SEM, n = 5, *P < 0.05 vs. NT ASO; E. Effect 
of ASO-mediated CD36 knockdown and pre-treatment with oleic acid (OA, 300 µmol/L) on MHEC and MLEC new 
vessel formation compared to control (CTRL) ECs in Matrigel tube formation assays. Scale bars represent 100 μm. 
Histograms show fold change in number of well-defined closed tube structures. Data represent mean ± SEM, n = 5, 
*P < 0.05 vs. NT ASO. Two-way ANOVA statistical tests were used to determine statistical significance.
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Figure 4. Effect of oleic acid on gene expression of endothelial and angiogenic markers in CD36-deficient MHECs. 
Effect of oleic acid (OA, 300 µmol/L) and siRNA-mediated CD36 knockdown on MHEC endothelial and angiogenic 
marker mRNA expression: (A) CD36, CD31, eNOS (B) VEGFα, VEGFR2, VEGFβ, VEGFR1 and (C) MMP9, MMP2, 
TIMP1, TIMP2, TIMP3, TIMP4 assessed by quantitative realtime PCR (qRT-PCR) normalized to 18S mRNA expres-
sion. Histograms show fold change in mRNA expression compared to NT siRNA ECs. Data represent mean ± SEM, 
n = 6, *P < 0.05 vs. NT siRNA, °P < 0.05 vs. NT siRNA + OA, #P < 0.05 vs. CD36 siRNA; (D) MMP9/MMP2 release 
assessed by colorimetric ELISA assays determined at 450 nm. Histograms show relative units (RU) of MMP release 
in supernatant samples of MHECs and MLECs treated with BSA (CTRL) or BSA-bound OA (OA) for 16 hours. Data 
represent mean ± SEM, n = 7, **P < 0.01 vs. MHECs CTRL. Two-way ANOVA statistical tests were used to determine 
statistical significance.
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increased [37]. This study concluded that EC 
CD36 plays an important role in the selection 
of tissue fuel as it regulates heart and skeletal 
muscle FA delivery as well as glucose utiliza-
tion. We were interested in studying the eff- 
ects of endothelial-specific CD36 knockdown 
on muscle tissue expression of metabolic 
genes. We assessed whether CD36 loss in ECs 
affects post-ischemic recovery. Following HLI 
surgery in control EC-Cd36fl/fl and EC-Cd36-/- 
mice, muscle tissues were collected at days 7 
and 21 (Supplementary Figure 3). Using laser 
Doppler imaging, we compared relative blood 
flow recovery in the post-ischemic and sham 
limb (labeled normal muscle). Control EC- 
Cd36fl/fl mice showed some recovery by day 7 
and much more collateral vessel formation by 
day 21 (Figure 6A), whereas EC-Cd36-/- mice 
Figure 5. Effect of oleic acid on gene expression of metabolic markers and protein expression of AMPK in CD36-
deficient MHECs. Effect of oleic acid (OA, 300 µmol/L) and siRNA-mediated CD36 knockdown on MHEC metabolic 
gene mRNA expression: (A) PPARα, PPARδ, PPARγ (B) AMPKα, ATGL, FASN, PLIN2, Cpt1a. Cpt1b, GLUT4, and GLUT1. 
Histograms show fold change in mRNA expression compared to NT siRNA ECs. Data represent mean ± SEM, n = 5, 
*P < 0.05 vs. NT siRNA, °P < 0.05 vs. NT siRNA + OA, #P < 0.05 vs. CD36 siRNA; (C) Effect of oleic acid (OA, 300 
µmol/L) and insulin (50 units/mL) and siRNA-mediated CD36 knockdown on MHEC intracellular signaling proteins 
as assessed by western blot. Images of SDS-PAGE gels represent protein expression of phospho-AMPK, AMPK and 
housekeeping gene α-tubulin. Histograms show fold change in protein expression compared to NT siRNA ECs. Data 
represent mean ± SEM, n = 3, *P < 0.05 vs. NT siRNA. Two-way ANOVA statistical tests were used to determine 
statistical significance.
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had impaired vascular recovery at days 7 and 
21 post-ischemic injury (Figure 6A). Control 
and EC-Cd36-/- mice were compared to deter-
mine differences in blood flow recovery and 
collateral vessel formation. EC-Cd36fl/fl and 
EC-Cd36-/- mice showed increased blood flow 
recovery and new vessel formation over 7 and 
21 days post-ischemia compared to day 0. 
However, EC-Cd36-/- mice had only 50% recov-
ery by day 21 compared to control EC-Cd36fl/fl 
mice (Figure 6A). At day 21, control mice had 
significantly increased CD31 protein in HLI 
muscle compared to normal muscle (Figure 
6B).
Factors regulating angiogenesis in control EC-
Cd36fl/fl and EC-Cd36-/- mice
We compared baseline differences in endothe-
lial and angiogenic marker gene expression in 
muscle tissues of EC-Cd36-/- and EC-Cd36fl/fl 
mice. Considering most significant differences 
in blood flow recovery were at day 21 post- 
ischemia (Figure 6B), we focused on gene and 
protein regulation at day 21. 
This yielded similar results to the gene expres-
sion studies, which suggested reduced CD36 
expression limits post-ischemic CD31 increas-
es in HLI muscle of EC-Cd36-/- mice compared 
to control mice, reflecting less EC content 
and collateral vessel formation (Figure 7B-D). 
Gene regulation comparisons between normal 
and HLI muscle tissues from EC-Cd36-/- and 
EC-Cd36fl/fl mice at day 7 post-ischemia have 
been compiled in the supplementary data 
(Supplementary Figure 4A-C). 
At day 21, control mice had significantly 
increased CD31 expression in HLI muscle 
compared to normal muscle. EC-Cd36-/- mice 
showed increased CD31 in normal muscle 
compared to control mice (Figure 7B); how- 
ever, there were no further increases in CD31 
expression in HLI muscle 21 days post-isch-
emia. Assessment of CD31 protein levels by 
immunohistochemistry (Figure 6B) paralleled 
gene expression results, suggesting reduced 
CD36 expression limits post-ischemic CD31 
increases in HLI muscle of EC-Cd36-/- mice 
compared to control mice, reflecting less EC 
Figure 6. In vivo hindlimb ischemia in EC-specific CD36 knockout mouse model. A. Representative images of blood 
flow by Laser Doppler imaging of normal and HLI muscle tissues of LoxP and EC-CD36 KO mice at day 0 (immedi-
ately after HLI) and days 7 and 21 post-ischemia, n = 7. Quantification of laser Doppler images of blood flow recovery 
in normal and HLI muscle tissues of LoxP and EC-CD36 KO mice at day 0 (immediately after HLI) and days 7 and 
21 post-ischemia. Histograms show blood flow ratios of HLI muscle compared to normal muscle in control LoxP and 
EC-CD36 KO mice. Data represent mean ± SEM, n = 7, ***P < 0.001 vs. LoxP Day 0, ###P < 0.001 vs. EC-CD36 KO 
Day 0, °°P < 0.01 vs. LoxP Day 21; B. Representative images of immunohistochemical staining for CD36 and CD31 
expression in normal muscle and HLI muscle from control LoxP and EC-CD36 KO mice at day 21 post-ischemia, n 
= 4. Scale bars represent 100 μm and 200 μm. Two-way ANOVA statistical tests were used to determine statistical 
significance.
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Figure 7. Effect of EC-CD36 knockout in HLI mouse muscle tissues on endothelial, vascular and metabolic gene expression at 21 days post-HLI. In vivo hindlimb 
ischemia (HLI) mouse tissue mRNA expression in normal and HLI muscle tissues of LoxP and EC-CD36 KO mice of (A) baseline (day 0) vascular endothelial and 
angiogenic marker mRNA expression of CD36, CD31, Ki67, eNOS, MMP9, MMP2, VEGFα, VEGFR2, VEGFβ, VEGFR1, Cpt1a, GLUT1, PLIN2, and AMPKα assessed by 
quantitative realtime PCR (qRT-PCR). Histograms represent fold changes in mRNA expression normalized to RPS3 mRNA expression. Data represent mean ± SEM, n 
= 8, *P < 0.05 vs. normal muscle LoxP; (B) Day 21 post-ischemia mRNA expression of CD36, CD31, eNOS, Ki67, VEGFα, VEGFR2, VEGFβ, and VEGFR1. Histograms 
represent fold changes in mRNA expression normalized to RPS3 mRNA expression. Data represent mean ± SEM, n = 8, *P < 0.05, **P < 0.01, ***P < 0.001 vs. 
normal muscle LoxP; (C) Day 21 post-ischemia mRNA expression of MMP9, MMP2, TIMP1, TIMP2, TIMP3, and TIMP4. Histograms represent fold changes in mRNA 
expression normalized to RPS3 mRNA expression. Data represent mean ± SEM, n = 8, *P < 0.05, **P < 0.01 vs. normal muscle LoxP; (D) Day 21 post-ischemia 
mRNA expression of Cpt1a, GLUT1, and PLIN2. Histograms represent fold changes in mRNA expression normalized to RPS3 mRNA expression. Data represent 
mean ± SEM, n = 8, *P < 0.05, **P < 0.01 vs. normal muscle LoxP, °P < 0.01 vs. normal muscle EC-CD36 KO. One-way and two-way ANOVA statistical tests were 
used to determine statistical significance.
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content and collateral vessel formation. CD31, 
MMP2, VEGFα, VEGFβ, GLUT1, and AMPKα 
were significantly upregulated in muscle tis-
sues of EC-Cd36-/- mice compared to control 
mice, whereas VEGFR1 and PLIN2 were down-
regulated at baseline (day 0) (Figure 7A). 
We next asked whether post-ischemic in- 
creases in EC content were associated with 
changes in cell proliferation or reflected 
increased EC recruitment to sites of vascular 
injury. In control mice, HLI muscle at day 21 
showed reduced Ki67 expression, suggesting 
increases in CD31 and eNOS expression were 
not associated with higher EC proliferative 
potential (Figure 7B). This downregulation in 
Ki67 is expected, due to EC vascular-associat-
ed injury. EC-Cd36-/- mice did not show in- 
creased Ki67 expression at day 21 post-isch-
emia (Figure 7B). CD36 deficiency is not as- 
sociated with post-ischemic cell proliferation, 
which is consistent with our in vitro data show-
ing that CD36 knockdown does not alter cell 
proliferation (Figure 1B). Rather, collateral ves-
sel formation upon post-ischemic recovery may 
be due to recruitment of ECs from pre-existing 
vessels.
Having shown no changes in cell proliferation 
post-ischemia, we examined regulation of 
growth factors that drive EC recruitment to 
sites of vascular injury. At day 21 post-ische- 
mia, VEGFβ and VEGFR1 expression increas- 
ed in EC-Cd36-/- mice compared to control 
mice. Although knockout mice showed upregu-
lation of pro-angiogenic VEGFα in normal mus-
cle, no further increase occurred in HLI muscle 
(Figure 7B). Moreover, upregulation of anti-
angiogenic VEGFβ and VEGFR1 may contribute 
to the hindered recovery of EC-Cd36-/- mice, 
supporting that VEGFβ upregulation impairs 
angiogenesis (Figure 7A). 
MMP and TIMP regulation in EC-Cd36-/- mice
At day 21 post-ischemia, HLI muscle of EC- 
Cd36-/- mice only showed significant increases 
in MMP2 activity, but not MMP9 (Figure 7C). 
This supports our in vitro results showing that 
muscle-derived ECs (MHECs) release higher 
levels of MMP2 compared to MMP9 and may 
contribute more to repair processes (Figure 
4D). Hence, CD36 deficiency hinders angiogen-
ic potential of ECs.
In contrast, HLI muscle of control mice at day 
21 post-ischemia showed increased TIMP2, 
whereas HLI muscle in EC-Cd36-/- mice show 
increased TIMP1 and TIMP3, which explains 
the lack of MMP9 increase (Figure 7C). Alto- 
gether, these data suggest that TIMP upregula-
tion and the consequent MMP inhibition con-
tribute to limiting EC angiogenic potential dur-
ing vascular recovery. 
AMPK and metabolic gene regulation in EC-
Cd36-/- mice
Another pathway known to modulate angio- 
genesis is via AMPK [39-42]. Under hypoxic 
conditions, angiogenesis switches from VEGF- 
to AMPK-mediated angiogenesis [39, 40]. 
Moreover, CD36 dysfunction is associated 
with reduced lipid-sensing activity of AMPK 
[38], a metabolic regulator during nutrient 
deprivation, hypoxia, ischemia, and exercise 
[41]. EC-Cd36-/- mice show increased muscle 
AMPKα mRNA expression at baseline com-
pared to control mice (Figure 7A), correlating 
with our in vitro data that shows MHECs dis- 
play increased AMPKα mRNA expression upon 
CD36 knockdown (Figure 5B). In vitro, we 
show that MHECs exposed to high levels of 
OA increase protein expression of phospho-
AMPK (Figure 5C). These data suggest that 
CD36 is tightly involved in positively regulating 
EC angiogenic migratory function since regard-
less of the injury-induced increase in AMPK 
activity through phosphorylation, ECs did not 
overcome the anti-angiogenic effects of CD36 
inhibition.
Moreover, we investigated metabolic genes 
and noted no changes in Cpt1a at day 21 
post-ischemia. However, there was a signifi- 
cant increase in PLIN2 in HLI muscle of control 
mice and an even larger increase in PLIN2 in 
HLI muscle of EC-Cd36-/- mice, compared to 
their normal muscle (Figure 7D). GLUT1 was 
increased in normal muscle of EC-Cd36-/- 
mice and downregulated in HLI muscle of both 
EC-Cd36-/- and control mice (Figure 7D). 
Discussion
ECs regulate vascular repair by releasing auto-
crine and paracrine factors to maintain vascu-
lar integrity. Their interaction with other vascu-
lar cells is central to vascular function. ECs 
drive neovascularization through angiogenesis, 
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a process allowing for vascular repair and 
extension of the vascular system. However, 
dysfunctional ECs contribute to disease patho-
genesis by excessively upregulating or down-
regulating angiogenesis [7, 43]. 
We have uncovered a novel pro-angiogenic 
role for CD36, particularly as it relates to the 
function of CD36 as a FA transporter in ECs. 
Many studies investigated EC functional dys-
regulation in metabolic syndromes, diabetes, 
and obesity to better understand how this 
disruption promotes cardiovascular diseases 
[44]. Most studies focused on effects of high 
circulating glucose on EC function, leaving 
gaps in knowledge pertaining to the impact of 
high circulating FAs. Thus, we investigated the 
role of FA metabolism in EC repair. Our in vitro 
studies showed that LCFAs promote EC migra-
tion and invasion without modulating proli- 
feration. These effects were mediated via 
CD36, as CD36 knockdown negated them. In 
addition, EC-Cd36-/- mice showed defective 
angiogenesis after HLI, as assessed by blood 
flow imaging and endothelial angiogenic gene 
expression profiles. 
FAs induced EC migration and invasion; how- 
ever, FA-pretreated ECs lost their FA-induced 
increase in angiogenic properties and effects 
with CD36 inhibition. Moreover, MHEC and 
MLEC angiogenic functions were differentially 
regulated by VEGFs and MMPs. Angiogenic 
functions of muscle-derived macrovascular 
ECs (MHECs) are mainly driven by VEGFα and 
MMP2 release.
Vascular ECs from different tissues show 
differential angiogenic functions. We show 
that not all ECs react similarly to FA uptake 
through CD36. Microvascular ECs release 
more MMP9 and TIMP1, whereas macrova- 
scular ECs release more MMP2 [45, 46]. Our 
data support these claims since MHECs 
showed significantly higher MMP2 release 
compared to MLECs, and MMP2 was increas- 
ed in the presence of OA in MHECs. Hence, we 
associated increased uptake of FAs through 
CD36 to the upregulation of VEGFα whereby 
VEGFα, in turn, upregulates MMPs, providing a 
positive feedback communication between 
VEGFs and MMPs, as previously reported [4, 
47]. Blocking MMPs has also been previously 
reported to cause inhibition of EC migration 
[48, 49].
To translate our in vitro findings, we studied 
whether EC-Cd36-/- mice had a repair defect 
after HLI. CD36 deficiency hinders post-isch-
emic recovery compared to normal mice. By 
day 21 post-ischemia, HLI muscle of control 
mice showed upregulation of endothelial and 
angiogenic markers such as CD31, MMP9, 
and MMP2, whereas EC-Cd36-/- mice showed 
similar increases in normal muscle, but no 
further increase in the HLI muscle (Figure 7B, 
7C). Our data suggest that although CD36-
deficient mice have angiogenic factors requir- 
ed to induce vascular repair, they do so to a 
lesser extent compared to control mice. We 
associated the inhibition of further recovery to 
an upregulation of TIMP1 and TIMP3, which 
regulate MMP9 and MMP2 function. 
Several metabolic pathways modulate angio-
genesis. Insulin regulates vascular cell func-
tions and drives EC angiogenesis through 
stimulation of glucose transport, release of 
VEGF, induction of eNOS, and proliferation of 
cells via a mechanism that involves PI3K-Akt 
pathway activation [50]. 
Metabolic genes affect angiogenesis in ECs. 
Although ECs derive their energy mainly from 
glycolysis, during injury or in the absence of 
adequate glucose supply, ECs switch their 
metabolic flux to uptake and utilize FAs in an 
AMPK-dependent manner for energy [40]. An 
important factor shown to drive angiogenesis 
in ECs is insulin. Insulin potentiates the relea- 
se of vascular growth factors and promotes 
EC proliferation, migration, and new vessel 
formation [50]. Insulin activates PI3K-Akt 
through a phosphorylation mechanism, result-
ing in eNOS activation and NO production; 
this, in turn, regulates VEGF [50]. Insulin re- 
ceptor knockout mice display a deficiency in 
neovascularization [51, 52]. A similar effect is 
observed in FOXO1-deficient mice [53, 54], 
which show significant defects in embryonic 
vascular formation [55]. FOXO1 is a check- 
point regulator of vascular homeostasis, as it 
regulates genes involved in cell growth and 
survival [55]. Regarding metabolic gene re- 
gulation and its relation to angiogenesis, stud-
ies correlated FA oxidation and Cpt1a expres-
sion to increased lymphatic EC embryonic 
angiogenesis. In this study, we associate a 
novel role to metabolic genes in regulating 
angiogenesis during vascular repair [55]. 
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Recently, it has been shown that skeletal mus-
cle CD36 deficiency is associated with reduced 
cellular insulin signaling and increased phos-
phorylation of the insulin receptor [21]. 
AMPK is a cellular energy sensor that regulat- 
es ATP homeostasis and balances ATP produc-
tion and consumption. AMPK regulates EC 
angiogenesis by protecting cells from stres- 
sors like hypoxia, oxidative stress, and 
increased levels of glucose and FAs. AMPK 
mediates VEGF levels and VEGF-mediated 
angiogenesis [49, 56]. Under vascular injury, 
the AMPK pathway is activated in ECs as a 
protective survival mechanism and mediates 
vascular homeostasis [40, 57]. Moreover, the 
activation of endothelial AMPK promotes 
mitochondrial biogenesis and adaptation to 
stress via eNOS signaling [58]. We found 
that CD36 deficiency upregulated AMPKα 
gene expression and activity in macrovas- 
cular ECs, possibly as a compensatory mecha-
nism to maintain EC angiogenic function. 
However, changes in baseline AMPK expres-
sion did not overcome the defective response 
to ischemia observed with EC CD36 deficien- 
cy. Rather, CD36 inhibition hindered pro-migra-
tory changes reflected in normal cells ex- 
posed to FAs and pro-angiogenic reparative 
effects induced in normal tissues post-isch-
emia, regardless of AMPK increase. These 
data suggest that although CD36 deficiency 
may promote AMPK activity in vascular re- 
pair, this defect in CD36-mediated FA uptake 
simultaneously upregulates anti-angiogenic re- 
gulators such as VEGFβ/VEGFR1 and TIMPs. 
We suggest this is due to increased insulin 
sensitivity.
Figure 8. Mechanism of FA-mediated stimulation of EC angiogenic function via CD36. Increased FA uptake results in 
binding of these molecules to PPARs at the surface of the nucleus. In turn, PPARs translocate and dimerize with the 
nuclear receptor RXR resulting in the modulation of CD36 gene transcription. Functionally, FA uptake through the 
CD36 receptor results in the upregulation of mitochondrial Cpt1a and activation of AMPKα, which in turn increases 
VEGF and eNOS expression in ECs under ischemic conditions. This increase in angiogenic factors promotes EC re-
cruitment, migration, invasion and the formation of new vessels in muscle tissues during post-ischemic recovery. On 
the other hand, insulin receptor (IR) actions are modulated in a CD36-dependent manner preventing src-mediated 
phosphorylation leading to reduced PI3K/Akt signaling, which results in decreased VEGF and angiogenesis in ECs 
[38, 39].
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Our data demonstrate a novel role for CD36 in 
EC angiogenic function and vascular repair. We 
propose a mechanism for the effects of FA 
uptake on ischemic injury via CD36. Although 
ECs primarily utilize glucose for energy under 
quiescent conditions [59], we suggest that 
ECs utilize FAs to promote their migration and 
invasion, allowing for new vessel formation fol-
lowing vascular injury. Our study provides in- 
sights into the pro-angiogenic role of CD36 in 
ECs as a therapeutic target in peripheral va- 
scular disease, supporting that ECs utilize FA 
oxidation likely in an AMPK-dependent manner 
during glucose deprivation (Figure 8) [59, 60]. 
Further studies would be needed to decipher 
the alterations observed in the AMPK mecha-
nistic pathway as a result of ECs exposed to 
chronically high levels of FAs.
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Supplementary Figure 1. Effect of oleic acid on gene expression of endothelial and angiogenic markers in CD36-
deficient MLECs. Effect of oleic acid (OA, 300 µmol/L) and siRNA-mediated CD36 knockdown on MLEC endothelial 
and angiogenic marker mRNA expression: (A) CD36, CD31, eNOS (B) VEGFα, VEGFR2, VEGFβ, VEGFR1 and (C) 
MMP9, MMP2, TIMP1, TIMP2, TIMP3, TIMP4 assessed by quantitative realtime PCR (qRT-PCR) normalized to 18S 
mRNA expression. Histograms show fold change in mRNA expression compared to NT siRNA ECs. Data represent 
mean ± SEM, n=6, *p < 0.05 vs. NT siRNA, °p < 0.05 vs. NT siRNA + OA, #p < 0.05 vs. CD36 siRNA. Two-way ANOVA 
statistical tests were used to determine statistical significance.
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Supplementary Figure 2. Effect of oleic acid on gene expression of metabolic markers and protein expression of 
AMPK in CD36-deficient MLECs. Effect of oleic acid (OA, 300 µmol/L) and siRNA-mediated CD36 knockdown on 
MLEC metabolic gene mRNA expression: (A) PPARα, PPARδ, PPARγ (B) AMPKα, ATGL, FASN, PLIN2, Cpt1a. Cpt1b, 
GLUT4, and GLUT1. Histograms show fold change in mRNA expression compared to NT siRNA ECs. Data represent 
mean ± SEM, n=5, *p < 0.05 vs. NT siRNA, °p < 0.05 vs. NT siRNA + OA, #p < 0.05 vs. CD36 siRNA; (C) Effect of 
oleic acid (OA, 300 µmol/L) and insulin (50 units/mL) and siRNA-mediated CD36 knockdown on MLEC intracellular 
signaling proteins as assessed by western blot. Images of SDS-PAGE gels represent protein expression of phospho-
AMPK, AMPK and housekeeping gene α-tubulin. Histograms show fold change in protein expression compared to 
NT siRNA ECs. Data represent mean ± SEM, n=3. Two-way ANOVA statistical tests were used to determine statistical 
significance.
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Supplementary Figure 3. In vivo hindlimb ischemia (HLI) mouse model of peripheral vascular disease (A) Figure 
shows the timeline of surgery and recovery of LoxP control mice (EC-Cd36fl/fl) and EC-CD36 KO mice (EC-Cd36-/-) 
whereby recovery was monitored over 7 and 21 days. 
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Supplementary Figure 4. Effect of EC-CD36 knockout in HLI mouse muscle tissues on endothelial, vascular and 
metabolic gene expression at 7 days post-HLI. In vivo hindlimb ischemia (HLI) mouse tissue mRNA expression in 
normal and HLI muscle tissues of LoxP and EC-CD36KO mice of (A) day 7 post-ischemia mRNA expression of CD36, 
CD31, eNOS, Ki67, VEGFα, VEGFR2, VEGFβ, and VEGFR1. Histograms represent fold changes in mRNA expression 
normalized to RPS3 mRNA expression. Data represent mean ± SEM, n=8, *p < 0.05, **p < 0.01, ***p < 0.001 vs. 
normal muscle LoxP; (B) day 7 post-ischemia mRNA expression of MMP9, MMP2, TIMP1, TIMP2, TIMP3, and TIMP4. 
Histograms represent fold changes in mRNA expression normalized to RPS3 mRNA expression. Data represent 
mean ± SEM, n=8, *p < 0.05, **p < 0.01 vs. normal muscle LoxP, °p < 0.01 vs. normal muscle EC-CD36KO; (C) 
day 7 post-ischemia mRNA expression of Cpt1a, GLUT1, and PLIN2. Histograms represent fold changes in mRNA 
expression normalized to RPS3 mRNA expression. Data represent mean ± SEM, n=8, *p < 0.05, **p < 0.01 vs. 
normal muscle LoxP, °p < 0.01 vs. normal muscle EC-CD36 KO, #p < 0.01 vs. HLI muscle LoxP. Two-way ANOVA 
statistical tests were used to determine statistical significance.
